Best,
When AMBS first acquired LYMPRO back in 2012 they released the multivariate sens/spec #s of 98/96.


From the second paragraph:
Amarantus BioScience Licenses LymPro Alzheimer's Disease Diagnostic Blood Test

Download PDF



SUNNYVALE, Calif., Dec. 14, 2012 /PRNewswire/ -- Amarantus BioScience, Inc.

Quote:

---

LymPro was designed with the purpose of diagnosing Alzheimer's in its mild to moderate stage, a population of patients currently being tested in numerous clinical studies with amyloid-beta targeting strategies. LymPro works by identifying immune-based biomarkers in the blood of Alzheimer's patients, diagnosing Alzheimer's and allowing physicians to definitively differentiate Alzheimer's disease from other forms of dementia. This patient-specific identification has the potential to become an invaluable tool for Alzheimer's disease clinical trials, where there has been a well-documented history of patient recruitment errors related to inaccurate diagnosis of Alzheimer's. LymPro has completed two Phase 1 clinical studies in over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis. LymPro is ready to move into a Phase 2 validation study. If successful, LymPro can begin generating revenue as a laboratory developed test ("LDT" within 18 months of study initiation through commercial sales and through sales to companies performing Alzheimer's disease clinical research.

---

http://ir.amarantus.com/company-news/detail/4...blood-test

This PR also outlines the terms of the deal with MDx.

AMBS